Consortium-Based Open Innovation: Exploring a Unique and Optimal Model for Regional Biotechnology Industry
作者： Shintaro Sengoku
DOI: 10.1007/978-981-13-9053-1_7
关键词:
摘要: Developing high-tech start-ups has been embedded into political efforts that require a large, long-term investment whereas the uncertainty of research and development business risks are high. In biotechnology healthcare field, emergence new modalities such as cell gene therapy nanomedicine need to be implemented complying multidimensional societal requirements covers ethics, regulations adoption by citizens. Considering these issues, present chapter aims explore unique optimal innovation model for regional biotech industry in Japan—the consortium from viewpoints theories organisation on inter-firm collaboration, system intellectual property management. Next, cases entrepreneurial innovative activities around drug discovery firms Japan date provided, focusing fields advanced science technology way develop entrepreneurs start-up perspective sectorial systems. third section, order specifically examine challenges measures developing Japan, case newly developed cluster is examined. Conclusively, view direction boosting suitable environment proposed, with particular foci two non-technological elements—the design implementation ecosystem an R&D entrepreneurs, significance socioeconomic forms technologies properly high ethical, regulatory scientific linkages.
springer.com
sci-hub.se 参考文章(85)
C. Freeman, Technical Innovation, Diffusion, and Long Cycles of Economic Development Springer, Berlin, Heidelberg. pp. 295- 309 ,(1987) , 10.1007/978-3-662-10351-7_21
Takayuki Yamanaka, Shingo Kano, Patent term extension systems differentiate Japanese and US drug lifecycle management Drug Discovery Today. ,vol. 21, pp. 111- 117 ,(2016) , 10.1016/J.DRUDIS.2015.09.005
Shiaw Jia Eyo, A Comparison of Biotechnology Industry in Japan and Other Developed Countries Social Science Research Network. ,(2011) , 10.2139/SSRN.1878599
Gary P. Pisano, Science Business: The Promise, the Reality, and the Future of Biotech ,(2006)
Philip Nicholas Cooke, Knowledge Economies: Clusters, Learning and Cooperative Advantage ,(2001)
Janice M. Reichert, Trends in development and approval times for new therapeutics in the United States. Nature Reviews Drug Discovery. ,vol. 2, pp. 695- 702 ,(2003) , 10.1038/NRD1178
Israel M Kirzner, Entrepreneurial Discovery and the Competitive Market Process: An Austrian Approach Journal of Economic Literature. ,vol. 35, pp. 15- 52 ,(1997) , 10.4324/9780203465974-5
Bruce Booth, Rodney Zemmel, Prospects for productivity. Nature Reviews Drug Discovery. ,vol. 3, pp. 451- 456 ,(2004) , 10.1038/NRD1384
Hawa Issa Munisi, Hiroaki Kakihara, Shintaro Sengoku, Mitsuya Sakurai, The current status and value creation of unlisted Biotech Drug Discovery/Development Firms (Biotech DDFs) in Japan: A holistic approach portland international conference on management of engineering and technology. pp. 3612- 3620 ,(2014)
Open Innovation: The New Imperative for Creating and Profiting from Technology European Journal of Innovation Management. ,vol. 7, pp. 325- 326 ,(2004) , 10.1108/14601060410565074